A carregar...
Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States
INTRODUCTION: Data from the SINGLE trial demonstrated that 88% of treatment-naive HIV-1 patients treated with dolutegravir and abacavir/lamivudine (DTG+ABC/3TC) achieved viral suppression at 48 weeks compared with 81% of patients treated with efavirenz/tenofovir disoproxil fumarate/emtricitabine (EF...
Na minha lista:
| Publicado no: | J Int AIDS Soc |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
International AIDS Society
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4224816/ https://ncbi.nlm.nih.gov/pubmed/25394109 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7448/IAS.17.4.19605 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|